Trial Profile
An Open-label, Phase I Study in Healthy Male Subjects to Compare the Pharmacokinetics of LB80331 and LB80317, Metabolites of LB80380, After a Single Oral Administration of LB80380 Free Base 150 mg (60 mg + 90 mg) Tablet or LB80380 Maleate Tablet 183 mg (150 mg as a Free Base).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Besifovir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 24 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 05 Sep 2011 New trial record